Updated results from Phase 1/2 trial of Betalutin® in NHL accepted for presentation at the International Conference on Malignant Lymphoma in June
Oslo, Norway, 28 April 2017 Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated results from the ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) has been accepted for presentation at the International Conference on Malignant Lymphoma (14-ICML, June 14-17, Lugano, Switzerland). The poster will be presented by Dr. Arne Kolstad, Senior Consultant in Medical Oncology and Radiation Therapy at the Oslo University Hospital, Norwegian Radium Hospital, and the